1Chen S, Hong SW, Lglesias de la cruz MC, et al. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail, 2001, 23(4) :471 -481.
2Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin Ⅱ in diabetic nephropathy.Kidney lnt, 2000, 58(Suppl 77): s93 - s98.
3Singh R, Song RH, Alavi N, et al. High glucose decrease matrix metaLloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta. Exp Nephrol, 2001,9(4): 249 - 257.
4Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and TGF-beta: transforming our view of glomerulosclerosis and fibrosis build up. Semin Nephrol, 2003, 23(6): 532-543.
5Nicholas SB. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol, 2003, 49(8): 1319 - 1325.
6Schiffer M, Von Gersdoff G, Bitzer M, et al. Smad proteins and transforming growth factor-beta signaling. Kidney lnt, 2000, 58(Suppl 77): S45-S52.
7Abe H, Natsubara T, lehara N, et al.Type Ⅳ collegen is transcriptionlly regulated by smadlunder advanced glycation endproducts(AGES) stimulation. J Bid Chem,2004, 279(14) : 14201-14206.
8Liao J, Kobayashi N, Kanamum Y, et al. Effects of candesarton, an angiotensin Ⅱ typel receptor blocker on diabetic nephropathy in KK/Ta mice. J Nephrol, 2003, 16(6): 841 - 849.
9Hong SW, Isono M, Cben S, et al. Increased glomerular and tubular expression of transforming factor-bets, its type Ⅱ receptor,and activation of the smad signaling pathway in the db/db mouse. Am J Pathol, 2001,158(5): 1653 - 1663.
10Massague J, Wotton D. Transcriptional control by TGF-β/smad signaling system.EMBO J, 2000, 19(8): 1745 - 1754.
